【www.zhangdahai.com--护士节演讲稿】
[摘要] 目的 探讨CD44v6在乳腺癌及乳腺腺病中的表达变化与临床病理意义。方法 应用免疫组织化学方法,分别检测52例乳腺癌及15例乳腺腺病组织CD44v6的表达情况,分析其与临床病理参数的关系。结果 CD44v6在乳腺癌中的阳性表达率78.8%(41/52),在乳腺腺病中阳性表达率13.3%(2/15),其差异有统计学意义(P75%为4分。根据染色强度与阳性细胞百分比得分之积分为4级,即(-)为0分,弱阳性(+)为1～2分,阳性(++)为3～4分,强阳性(+++ )为5～6分。将A×B作为其染色的计数,只有A×B >3 分才算免疫反应阳性,并按乘积分数将染色结果分为:-(0～2 分)、+(大于2分)。
1.4 统计学处理
应用SPSS10.0软件进行χ2检验和Fisher确切概率法,P0.05)。
3 讨论
CD44是这几年来研究比较多的一类细胞黏附分子,是一组广泛分布在细胞表面的跨膜糖蛋白,参与细胞与间质、细胞与细胞之间的连接,根据其所含外显子的不同分为两种亚型:CD44v和CD44s。CD44蛋白有如下功能:①激活淋巴细胞;②诱导淋巴细胞通过血管壁;③与细胞骨架蛋白互相结合,参与伪足形成;④与细胞外基质中的胶原蛋白、透明质酸、层黏蛋白、纤黏蛋白等结合[5]。CD44在恶性肿瘤组织中主要表达于肿瘤细胞,促进肿瘤细胞的黏附和运动,特别是在促进淋巴结转移和浸润方面起很重要的作用,体外实验证明在肝细胞生长因子存在的情况下这种作用更为明显[6]。
CD44v6与乳腺癌预后的关系目前仍不十分明确。有研究表明,CD44v6的表达与患者的生存率无明显相关[7,8]。然而Kaufmann等[9] 的实验显示,CD44v6阳性患者与阴性的患者在随访9O个月后,阳性患者的总体生存率明显低于阴性患者,多因素分析的结果表明,CD44v6可以作为独立预后指标。Tempfer等[10]的研究显示,乳腺癌中CD44v6阳性组的5年生存率明显低于阴性组,差异有显著性。我们的研究显示,CD44v6在乳腺腺病与乳腺癌的阳性表达率有显著差异(P [参考文献]
[1] Faleiro-Rodrigues C,Lopes C. E-cadherin,CD44 and CD44v6 in squamous intraepithelial lesions and invasive carcinomas of the uterine cervix:an immunohistochemical study[J]. Pathobiology,2004,71(6):329-336.
[2] Kobel M,Weichert W,Cruwell K,et al. Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis[J]. Virchows Arch,2004,445(5):456-464.
[3] Nozoe T,Kohnoe S,Ezaki T,et al. Significance of immunohistochemical over-expression of CD44v6 as all indicator of m alignant potential in esophageal squamous cell carcinoma[J]. J Cancer Res Clin Oncol,2004,130(6):334-338.
[4] Liu WH,Kaur M,Wang G,et al. Inverse PCR-based RFLP scanning identifies low-level mutation signatures in colon cell and turmors[J]. Cancer Res,2004,64:2544-2551.
[5] Bourguignon LY,Singleton PA,Diedrich F,et a1. CD44 inter action with Na+-H+ exchanger(NHE1)creats acidic micro-environments leading to hyaluronidase 2 and cathepsin-B activation and breast tumor cell invasion[J]. J Biol Chem,2004,279(26):26991-27007.
[6] Mine S,Fujisaki T,Kawahara C,et al. Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up regulation of CD44[J]. Exp Cell Res,2003,288(1):189-197.
[7] Tokue Y,Matsumura Y,Katsumata N,et al. CD44 variant expression and breast cancer prognosis[J]. Jpn J Cancer Res,1998,89(3):283-290.
[8] Diaz L K,Zhou X,Wright E T,et al. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma[J]. Clin Cancer Res,2005,11(9):3309-3314.
[9] Kaufmann M,Heider KH,Sinn HP,et al. CD44 variant exon epitopes in primary breast cancer and length of survival[J]. Lancet,1995,345(8950):615-619.
[10] Tempfer C,Losch A,Heinzl H,et al. Prognostic value of immnunohistochemically detected CD44 isoforms CD44v5,CD44v6 and CD44v7-8 in human breast cancer[J]. Eur J Cancer,1996,32A(11):2023-2025.
(收稿日期:2009-12-16)
